The most effective MS treatments: ranked from strongest to weakest (2026)
Which multiple sclerosis therapy actually reduces relapses, new lesions and disability progression the most? A full ranking of approved DMTs — from AHSCT and alemtuzumab, through anti-CD20 agents (Briumvi, Kesimpta, Ocrevus) and natalizumab, down to interferons and glatiramer acetate — with pivotal trial percentages, 2024–2026 network meta-analyses, and an honest look at the risk each option carries.
I am writing this from a personal angle too: I have lived with MS for years, and I know how much a calm explanation matters. There is no single "best MS drug" for everyone. There is, however, a clear efficacy hierarchy confirmed by pivotal randomised trials and recent network meta-analyses (2023–2025) [1](#ref-1)[3](#ref-3)[4](#ref-4):
AHSCT (stem cell transplant) ≥ alemtuzumab ≈ ublituximab ≈ ofatumumab ≈ ocrelizumab ≈ natalizumab > cladribine > S1P modulators (fingolimod > ozanimod ≈ ponesimod ≈ siponimod) > dimethyl fumarate > teriflunomide > interferons ≈ glatiramer acetate.
But "most effective" is not the same as "best for you". The strongest drugs carry the highest risk (PML, secondary autoimmunity, infections, and with AHSCT procedural mortality). The decision is always a balance: how aggressive the disease is now versus how much risk is justified.
How efficacy is actually measured
When you read trial percentages, note that three different outcomes are being reported — a drug can look excellent on one and weak on another:
- ARR (annualised relapse rate) — how much the drug cuts relapses per year. The easiest outcome to move, which is why these numbers are the biggest.
- MRI activity — reduction in new T2 and gadolinium-enhancing lesions. The most sensitive marker of inflammation.
- CDP (confirmed disability progression) — the only outcome that really reflects long-term function. The hardest to move, which is why these numbers are the most modest.
One more trap: the comparator is not the same across trials. Older drugs were tested against placebo (easier to show a big effect), newer ones against an active drug (teriflunomide or interferon). So natalizumab 68% versus placebo and ublituximab 59% versus teriflunomide cannot be compared head to head — that is exactly what network meta-analyses are for.
The ranking: most effective to least effective
AHSCT — autologous haematopoietic stem cell transplantation
Efficacy: the highest recorded. Compared with fingolimod, natalizumab and ocrelizumab in highly active RRMS, AHSCT was superior on relapse rate and NEDA status [13](#ref-13). Over 70% of patients show no evidence of disease activity 4–5 years after the procedure.
Who it is for: younger patients, short disease duration, highly inflammatory RRMS that fails high-efficacy DMTs. Not for typical non-inflammatory progressive MS.
Risk: procedural mortality around 0.2–0.3% in experienced centres, infertility, severe infections during aplasia. The 2024 ECTRIMS/EBMT recommendations define exactly who is and is not a candidate [14](#ref-14).
Full guide: [Stem cell transplantation in MS](/blog/transplantacija-maticnih-celija-ms-vodic).
Alemtuzumab (Lemtrada)
Efficacy: ARR reduced 49–55% versus interferon beta-1a, roughly 92% fewer gadolinium-enhancing lesions, and 30–42% reduction in 6-month CDP (CARE-MS I and II).
Advantage: given as two short courses (5 + 3 days) with an effect that lasts years without further treatment.
Risk: the most serious of the whole class — secondary autoimmunity in roughly one third of patients (most often thyroid disease, but also ITP and autoimmune kidney disease), infusion reactions, rare stroke and arterial dissection. Requires monthly blood and urine monitoring for 4 years after the last dose.
Ublituximab (Briumvi)
Efficacy: ARR reduced 59% and 49% versus teriflunomide (ULTIMATE I and II, NEJM 2022) [2](#ref-2) and ~97% fewer T1 gadolinium-enhancing lesions — the strongest MRI suppression recorded in the anti-CD20 class. A 2024 network meta-analysis confirmed it sits alongside ocrelizumab and ofatumumab [4](#ref-4).
Advantage: after the first dose, the infusion takes only 1 hour every 6 months.
Risk: infusion reactions, hypogammaglobulinaemia, increased infection risk. Not yet reimbursed in Serbia.
Ofatumumab (Kesimpta)
Efficacy: ARR reduced 50–58% versus teriflunomide (ASCLEPIOS I and II), ~97% fewer gadolinium-enhancing lesions, 34% reduction in 3-month CDP.
Advantage: the only anti-CD20 given as a monthly self-administered subcutaneous injection at home — no infusion centre needed.
Risk: injection-site reactions, falling immunoglobulins with long-term use, infections. Full guide: [Kesimpta (ofatumumab)](/blog/kesimpta-ofatumumab-kompletan-vodic-multipla-skleroza-srbija).
Ocrelizumab (Ocrevus)
Efficacy: ARR reduced 46–47% versus interferon beta-1a (OPERA I and II), 94–95% fewer gadolinium-enhancing lesions, 40% reduction in CDP. The only drug with a proven (modest, 24%) effect in primary progressive MS — the ORATORIO trial.
Advantage: infusion twice a year, the largest global experience and the longest data in the anti-CD20 class.
Risk: infections, hypogammaglobulinaemia, a breast cancer signal from the trial programme (a large 2024 analysis found overall malignancy risk on anti-CD20 therapy remains low but warrants routine screening) [12](#ref-12). Full guide: [Ocrevus (ocrelizumab)](/blog/ocrevus-okrelizumab-kompletan-vodic-multipla-skleroza-srbija).
Natalizumab (Tysabri)
Efficacy: 68% ARR reduction versus placebo (AFFIRM) — the single largest number in the literature, 92% fewer new T2 lesions, 42–54% reduction in sustained disability. The fastest onset of action of any DMT.
Risk: PML (progressive multifocal leukoencephalopathy) — a potentially fatal JC virus brain infection. Risk depends on three factors: JCV antibody status, treatment duration beyond 2 years, and prior immunosuppression. In the highest-risk stratum it approaches 1 in 100. In JCV-negative patients the risk is very low, with retesting every 6 months.
Full guide: [Tysabri (natalizumab)](/blog/tysabri-natalizumab-kompletan-vodic-multipla-skleroza-srbija).
Cladribine (Mavenclad)
Efficacy: ARR reduced 58% versus placebo (CLARITY), 86% fewer gadolinium-enhancing lesions, 33% reduction in 6-month CDP. A large real-world comparison (MSBase, 2024) found cladribine comparable to natalizumab, ocrelizumab and alemtuzumab on relapses and progression [5](#ref-5) — which places it higher than the CLARITY numbers alone would suggest.
Advantage: tablets, a total of 20 dosing days over 2 years, then a treatment-free period.
Risk: lymphopenia, herpes zoster, mandatory contraception (teratogenicity). Full guide: [Mavenclad (cladribine)](/blog/mavenclad-kladribin-kompletan-vodic-multipla-skleroza-srbija).
Fingolimod (Gilenya)
Efficacy: ARR reduced 48–52%, new T2 lesions down 74–82%, CDP 30% (FREEDOMS, TRANSFORMS). The first oral MS drug and still the strongest in the S1P class.
Risk: first-dose bradycardia (six hours of ECG monitoring required), macular oedema, infections, rare PML. Important: abrupt discontinuation can trigger a severe rebound relapse — never stop without a neurologist-guided plan.
Siponimod (Mayzent)
Efficacy: ARR reduced 55% in active disease and — most importantly — a 21% reduction in 3-month CDP in secondary progressive MS (EXPAND). The only S1P modulator with a formal SPMS label.
Risk: as for fingolimod, plus mandatory CYP2C9 genotyping before starting. Patient experiences: [Siponimod (Mayzent)](/blog/siponimod-mayzent-iskustva-pacijenata-multipla-skleroza).
Ozanimod (Zeposia)
Efficacy: ARR reduced 38–48% versus interferon (SUNBEAM, RADIANCE), 48–63% fewer gadolinium-enhancing lesions, no significant effect on CDP.
Advantage: a milder cardiac and hepatic profile than fingolimod. Registered in Serbia but not reimbursed.
Ponesimod (Ponvory)
Efficacy: ARR reduced 30.5% versus teriflunomide (OPTIMUM), 56% fewer combined unique active lesions, no CDP difference.
Advantage: the best fatigue and quality-of-life data in the S1P class and a short half-life (cleared quickly, useful before pregnancy or surgery).
Dimethyl fumarate (Tecfidera)
Efficacy: ARR reduced 44–53% versus placebo (DEFINE, CONFIRM), 85–90% fewer new T2 lesions, CDP 21–38%.
Advantage: the oral drug with the longest safety record in the middle efficacy tier.
Risk: flushing and gastrointestinal upset in the first weeks, lymphopenia — rare PML cases have occurred with prolonged severe lymphopenia. Full guide: [Tecfidera (dimethyl fumarate)](/blog/tecfidera-dimetil-fumarat-kompletan-vodic-multipla-skleroza-srbija).
Teriflunomide (Aubagio)
Efficacy: ARR reduced 31–36% versus placebo (TEMSO, TOWER), CDP 24–30%.
Risk: hepatotoxicity, hair thinning, and serious teratogenicity with a long washout (up to 2 years, or accelerated with cholestyramine). Not a first choice for women planning pregnancy.
Interferon beta (Avonex, Rebif, Betaferon, Extavia)
Efficacy: ARR reduced 18–33% versus placebo, active lesions down 50–78%, modest and inconsistent effect on CDP.
Advantage: more than 30 years of safety data, safe for long-term use, well characterised in pregnancy.
Risk: flu-like symptoms after injections, injection-site reactions, raised liver enzymes, neutralising antibodies that erode efficacy over time.
Glatiramer acetate (Copaxone)
Efficacy: ARR reduced 29–34%, gadolinium-enhancing lesions down 29–35%, no significant effect on disability progression.
Advantage: the best safety profile of any DMT — not an immunosuppressant, no blood monitoring required, and the safest option in pregnancy.
Risk: injection-site reactions, lipoatrophy, an occasional post-injection systemic reaction (chest tightness, flushing) that is unpleasant but harmless. Full guide: [Copaxone (glatiramer acetate)](/blog/copaxone-glatiramer-acetat-kompletan-vodic-multipla-skleroza-srbija).
Progressive MS is a separate story
Almost all the numbers above apply to relapsing-remitting MS. In progressive disease without inflammation, the efficacy of every drug drops sharply:
- Tolebrutinib (a BTK inhibitor) showed a 31% reduction in the risk of 6-month confirmed disability progression in non-relapsing SPMS in the HERCULES trial — the first oral drug with a positive effect on progression independent of relapse activity [6](#ref-6)[8](#ref-8).
- Siponimod remains the only approved S1P with an SPMS indication (21% CDP).
- Ocrelizumab is the only drug with a PPMS indication (24% CDP, ORATORIO), and mainly in younger patients with active MRI lesions.
More on new drugs: [Latest approved MS drugs 2026](/blog/najnoviji-odobreni-lekovi-multipla-skleroza-2026-tolebrutinib-cenrifki).
Early high-efficacy treatment or gradual escalation?
This is the biggest open question in MS neurology today. Two large pragmatic trials — DELIVER-MS and TREAT-MS — are directly comparing the two strategies: starting immediately with a high-efficacy drug versus starting milder and escalating [9](#ref-9)[10](#ref-10)[11](#ref-11).
Definitive results are expected in 2026–2027, but registry data (MSBase, Swedish and Danish registries) consistently favour early high-efficacy treatment for long-term disability. The practical consequence: more and more European MS centres are abandoning the old "start low and see" logic in patients with poor prognostic markers (high lesion load, spinal cord lesions, incomplete recovery from the first relapse, male sex, later onset).
What actually determines your treatment choice
A neurologist weighs far more than the ranking:
1. Disease activity — relapses in the last 12–24 months and new MRI lesions.
2. Prognostic markers — spinal cord and brainstem lesions, incomplete relapse recovery, high baseline EDSS.
3. JCV status — positive status rules out natalizumab as a long-term option.
4. Family planning — teriflunomide and cladribine are excluded; glatiramer and interferons are safest.
5. Comorbidities — cardiac arrhythmia rules out the S1P class; chronic infections complicate anti-CD20 therapy.
6. Route of administration — a tablet at home versus an infusion every 6 months is not a trivial difference for adherence.
7. Availability and reimbursement — in Serbia, Briumvi, Zeposia and Ponvory are registered but not reimbursed, while Ocrevus, Kesimpta, Tysabri, Mavenclad, Gilenya, Mayzent, Tecfidera, Aubagio, interferons and Copaxone are available through MS centres (List C). Details: [MS drugs in Serbia and RFZO](/blog/lekovi-za-ms-srbija-rfzo-recept) and [Cost of DMTs](/blog/cena-dmt-lekova-multipla-skleroza-srbija-godisnje).
What no drug can do for you
Alongside DMTs, measures that need no prescription have proven effects:
- Stopping smoking — smokers progress up to 50% faster.
- Regular physical activity — slows brain atrophy and reduces fatigue. See [exercises by EDSS level](/blog/joga-multipla-skleroza-edss-nivoi).
- Vitamin D in target range — [Vitamin D and MS](/blog/vitamin-d-ms-nauka).
- Treating depression and sleep disorders — directly changes the perceived severity of the disease.
- Symptomatic therapy — baclofen and tizanidine for spasticity, amantadine or modafinil for fatigue, dalfampridine for walking, gabapentinoids for neuropathic pain, anticholinergics and catheterisation for bladder problems. These do not change the disease course, but they change daily life.
If the question is "which drug suppresses inflammation hardest" — the answer is AHSCT, then alemtuzumab, then the anti-CD20 agents and natalizumab. If the question is "which drug is best for me" — the answer depends on disease activity, JCV status, family plans, comorbidities and what is genuinely available at your MS centre. The biggest mistake is not choosing a "weaker" drug; it is delaying treatment or stopping without a plan. Early, consistent treatment is the one factor that moves long-term outcomes in every registry.
Key studies mapped to claims
Which claim in this article relies on which reference.
- DMT efficacy hierarchy: Puente-Hurtado et al., J Comp Eff Res 2023 [1](#ref-1); Lucchetta et al., network meta-analysis 2024 [3](#ref-3); BMC Neurol 2025 [16](#ref-16).
- Ublituximab: 59%/49% ARR reduction and ~97% MRI suppression: ULTIMATE I and II, NEJM 2022 [2](#ref-2); network meta-analysis, Front Neurol 2024 [4](#ref-4).
- Cladribine comparable to natalizumab, ocrelizumab and alemtuzumab in practice: Roos et al., Mult Scler 2024 (MSBase) [5](#ref-5).
- Tolebrutinib and the 31% progression reduction in non-relapsing SPMS: HERCULES, NEJM 2025 [6](#ref-6); Sanofi release 2024 [8](#ref-8).
- AHSCT superior to fingolimod, natalizumab and ocrelizumab: Boffa et al., Neurology 2023 [13](#ref-13); ECTRIMS/EBMT recommendations, Nat Rev Neurol 2024 [14](#ref-14); JNNP 2024 [15](#ref-15).
- Malignancy risk on anti-CD20 therapy: Front Neurol 2024 [12](#ref-12).
- Early high-efficacy versus escalation: DELIVER-MS [9](#ref-9); TREAT-MS [10](#ref-10); Cleveland Clinic review 2025 [11](#ref-11).
Sources and references
1. {#ref-1} Puente-Hurtado I et al. *Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis.* J Comp Eff Res. 2023;12(7):e230016. [PMC10508312](https://pmc.ncbi.nlm.nih.gov/articles/PMC10508312/).
2. {#ref-2} Steinman L et al. *Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.* N Engl J Med. 2022;387:704–714. [NEJMoa2201904](https://www.nejm.org/doi/full/10.1056/NEJMoa2201904).
3. {#ref-3} Lucchetta RC et al. *Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.* 2024. [PubMed 38174776](https://pubmed.ncbi.nlm.nih.gov/38174776/).
4. {#ref-4} Moloney E et al. *Comparative efficacy and tolerability of ublituximab versus other monoclonal antibodies in relapsing MS: a network meta-analysis.* Front Neurol. 2024;15:1479476. [PMC11659144](https://pmc.ncbi.nlm.nih.gov/articles/PMC11659144/).
5. {#ref-5} Roos I, Sharmin S et al. *Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in RRMS.* Mult Scler. 2024. [DOI: 10.1177/13524585241267211](https://journals.sagepub.com/doi/10.1177/13524585241267211).
6. {#ref-6} Fox RJ, Bar-Or A et al. *Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis (HERCULES).* N Engl J Med. 2025. [NEJMoa2415988](https://www.nejm.org/doi/full/10.1056/NEJMoa2415988).
7. {#ref-7} Sanofi. *Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in MS.* April 2025. [sanofi.com](https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-08-17-11-11-3057931).
8. {#ref-8} Sanofi. *Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression (HERCULES).* September 2024. [sanofi.com](https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-20-09-30-00-2949552).
9. {#ref-9} DELIVER-MS Trial. ClinicalTrials.gov NCT03535298. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03535298).
10. {#ref-10} TREAT-MS Trial. ClinicalTrials.gov NCT03500328. [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03500328).
11. {#ref-11} Cleveland Clinic ConsultQD. *Early Intensive or Escalation Therapy for Relapsing-Remitting Multiple Sclerosis?* April 2025. [consultqd.clevelandclinic.org](https://consultqd.clevelandclinic.org/early-intensive-or-escalation-therapy-for-relapsing-remitting-multiple-sclerosis).
12. {#ref-12} *Risk of malignancy and the use of disease-modifying therapy in multiple sclerosis.* Front Neurol. 2024;15:1492678. [frontiersin.org](https://www.frontiersin.org/journals/neurology/articles/10.3389/fneur.2024.1492678/full).
13. {#ref-13} Boffa G et al. *Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active RRMS.* Neurology. 2023. [PMC10186210](https://pmc.ncbi.nlm.nih.gov/articles/PMC10186210/).
14. {#ref-14} Muraro PA et al. *Autologous haematopoietic stem cell transplantation for MS and NMOSD — recommendations from ECTRIMS and EBMT.* Nat Rev Neurol. 2024. [nature.com](https://www.nature.com/articles/s41582-024-01050-x).
15. {#ref-15} *Effectiveness of AHSCT versus natalizumab in progressive multiple sclerosis.* J Neurol Neurosurg Psychiatry. 2024. [jnnp.bmj.com](https://jnnp.bmj.com/content/early/2024/03/27/jnnp-2023-332790).
16. {#ref-16} *Comparative effectiveness of disease-modifying therapies for highly active RRMS despite previous treatment: a network meta-analysis.* BMC Neurol. 2025;25. [springer.com](https://link.springer.com/article/10.1186/s12883-025-04338-7).
*This article is educational and does not replace advice from a neurologist. An efficacy ranking is not a treatment recommendation — therapy choice depends on your individual factors and is made only with your MS centre physician.*